Information  X 
Enter a valid email address

Alliance Pharma PLC (APH)

  Print          Annual reports

Wednesday 01 July, 2020

Alliance Pharma PLC

Block Listing Six Monthly Return

RNS Number : 7671R
Alliance Pharma PLC
01 July 2020


For immediate release

1 July 2020





("Alliance" or the "Company")


Block Listing Six Monthly Return


Name of applicant:


Names of schemes:

a)  The Alliance Pharma plc Approved Share Option Plan 2005

b)  The Alliance Pharma plc Share Option Plan 2006

c)  The Alliance Pharma plc Company Share Option Plan 2015

Period of return:


28 December 2019


28 June 2020

Number of securities originally admitted at date of admission:

25,000,000 ordinary shares of 1p each

28 June 2017

Balance of unallotted securities under schemes from previous return:

a)  549,074

b)  6,111,334

c)  637,576

Plus:   The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):

a)  160,000

b)  Nil

c)  14,840,000

Less:   Number of securities issued/allotted under schemes during period:

a)  352,538

b) 748,556

c)  554,351

Equals:   Balance under schemes not yet issued/allotted at end of period:

a)  356,536

b)  5,362,778

c)  14,923,223


Name of contact:

Chris Chrysanthou, Company Secretary

Telephone number of contact:

Tel. +44 (0)1249 705166


For further information:


Alliance Pharma plc    + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer  


Buchanan         + 44 (0) 20 7466 5000

Mark Court / Hannah Ratcliff


Numis Securities Limited         + 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

Corporate Broking: James Black


Investec Bank plc     +44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar


About Alliance Pharma

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website    


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t